drugset / Trial / NCT00476112
A Phase II/III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Flutter
RandomizedParallel-groupTriple-blindTreatment
Summary
This study will attempt to demonstrate the effectiveness of RSD1235 in the conversion of atrial flutter (AFL) to sinus rhythm.
Timeline
- Start
- 2003-08
- Primary completion
- 2004-09
- Completion
- 2004-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vernakalant | Other / unclassified | 2 mg/kg | Intravenous |
| Subject | Vernakalant | Other / unclassified | 3 mg/kg | Intravenous |